![]() |
Name |
Daldiniol B
|
Molecular Formula | C12H10O3 | |
IUPAC Name* |
4-methoxy-3-(3-oxobut-1-ynyl)benzaldehyde
|
|
SMILES |
COc1ccc(C=O)cc1C#CC(C)=O
|
|
InChI |
InChI=1S/C12H10O3/c1-9(14)3-5-11-7-10(8-13)4-6-12(11)15-2/h4,6-8H,1-2H3
|
|
InChIKey |
DLHHALLWAQYTGT-UHFFFAOYSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 202.21 | ALogp: | 1.4 |
HBD: | 0 | HBA: | 3 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 43.4 | Aromatic Rings: | 1 |
Heavy Atoms: | 15 | QED Weighted: | 0.544 |
Caco-2 Permeability: | -4.482 | MDCK Permeability: | 0.00001960 |
Pgp-inhibitor: | 0.002 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.053 | 20% Bioavailability (F20%): | 0.033 |
30% Bioavailability (F30%): | 0.451 |
Blood-Brain-Barrier Penetration (BBB): | 0.585 | Plasma Protein Binding (PPB): | 75.13% |
Volume Distribution (VD): | 1.156 | Fu: | 5.54% |
CYP1A2-inhibitor: | 0.922 | CYP1A2-substrate: | 0.838 |
CYP2C19-inhibitor: | 0.684 | CYP2C19-substrate: | 0.474 |
CYP2C9-inhibitor: | 0.445 | CYP2C9-substrate: | 0.73 |
CYP2D6-inhibitor: | 0.008 | CYP2D6-substrate: | 0.516 |
CYP3A4-inhibitor: | 0.053 | CYP3A4-substrate: | 0.303 |
Clearance (CL): | 7.188 | Half-life (T1/2): | 0.584 |
hERG Blockers: | 0.009 | Human Hepatotoxicity (H-HT): | 0.037 |
Drug-inuced Liver Injury (DILI): | 0.838 | AMES Toxicity: | 0.846 |
Rat Oral Acute Toxicity: | 0.045 | Maximum Recommended Daily Dose: | 0.806 |
Skin Sensitization: | 0.945 | Carcinogencity: | 0.882 |
Eye Corrosion: | 0.986 | Eye Irritation: | 0.995 |
Respiratory Toxicity: | 0.981 |